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Abstract
Background. An increased level of apo B and decreased level of apo A-1 are thought to be better 
predictors of myocardial infarction than conventional lipid parameters in healthy individuals and/
or have coronary artery disease risk factors. Literatures said that HDL, LDL and apolipoprotein 
may have a role in haemostatic and thrombotic process. The present study aimed to investigate 
whether apo B/ apo A-1 ratio has a predictive role in hospitalised ACS patients to develop major 
adverse cardiac events (MACE).
Methods.We performed a prospective cohort study and examined 182 ACS patients hospitalised 
in dr. Sardjito General Hospital Yogyakarta consecutively since September 2013, and evaluated 
ischaemia heart disease risk factors, measured concentration of apo B/apo A-1 ratio and 
conventional lipid parameters from plasma, and fi nally assessed the in-hospital MACE outcome. 
Apo B/Apo A-1 ratio cut off point in this study was taken from ROC curve analysis. Relation between 
in-hospital MACE with level of apo B/apo A-1 ratio was analysed using SPSS.
Results. From 182 ACS subjects, 51 patients had MACE (MACE group) and 131 patients didn’t 
develop MACE (non-MACE group). From ROC curve, we set cut off point for apo B/apo A-1 ratio 
was 0,865. Subjects with an apo B/apo A-1 ratio ≥0,865 had a signifi cantly increased risk to suffer 
a cardiovascular event (MACE) during in-hospital follow-up. In a multiple logistic regression model, 
elevated apo B/apo A-1 ratio was an independent predictor for MACE during in-hospital follow-up 
(OR 3,17; 95%CI 1,299 - 7,738; p = 0,011).
Conclusion. The results showed that the elevated apo B/apo A-1 ratio ≥0,865 was an independent 
predictor of MACE, with three-folds increase of risk compared to group of apo B/apo A-1 ratio < 
0.865, during in-hospital follow-up in ACS patients.
Keywords: apolipoprotein B; apolipoprotein A-1; apolipoprotein ratio; acute coronary syndrome; 
major adverse cardiovascular events
high triglycerides, high apolipoprotein B (apo 
B), low HDL (high density lipoprotein) and low 
apolipoprotein A-1 (Apo A-1).2,3 Among patients 
who have recently experienced ACS, intensive 
statin therapy provides protection against death 
and MACE compared to standard therapy. 4,5
Currently, studies that reveal apolipoprotein 
as a better MACE predictor than the conventional 
lipid parameter are frequently found. Apolipoprotein 
B (apo B) is a protein found on the surface of 
LDL, VLDL (very low density lipoprotein) and 
chylomicrons. Apolipoprotein A-1 (Apo A-1) found 
on the surface of the HDL particle. Some of these 
studies said the value of apo B/apo A-1 ratio is 
an excellent tool for assessing cardiovascular 
risk. This ratio refl ects the relationship between 
the pro-atherogenic effects of apo B-containing 
lipoproteins and anti-atherogenic fraction of 
HDL. The higher the apo B/apo A-1 ratio group, 
Background
Acute coronary syndrome (ACS) is an 
event which is marked by changes in coronary 
circulation, generally in the form of a reduction or 
cessation of blood fl ow in the coronary arteries, 
which is generally caused by the formation of a 
blood clot on the ruptured atherosclerotic plaque. 
A good indicator is required for risk assessment of 
major cardiovascular events (MACE).1
Lipid profile and lipoprotein particles 
determines the ability of plasma lipids in the 
formation of atherosclerotic plaque. Among the 
risk factors that have been identifi ed as a risk 
factor for coronary heart disease, some constituent 
components of the lipid and lipoprotein known as a 
mediator are considered as coronary heart disease 
markers. The lipid components here particularly 
are higher plasma total cholesterol, high LDL 
cholesterol (low density lipoprotein) cholesterol, 
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the higher the risk MACE, namely the risk of 
myocardial infarction and other cardiovascular 
manifestations .6,7 Some studies suggest that HDL 
lipoprotein and its carrier which is apolipoprotein 
A-1, not only it has a “reverse cholesterol transport, 
but also has antioxidant effects, anti-infl ammatory, 
antithrombotic on vascular endothelial cells. 
Moreover, it is also able to prevent further vascular 
endothelial dysfunction, plaque rupture, thrombosis 
arterial and also inhibit the atherosclerosis and 
restenosis process.8
In regards of method, there are some 
advantages in measurement of apolipoprotein 
over conventional lipid measurement parameter. 
In standard LDL measurement, Friedwald formula 
determined by triglycerides levels requires fasting 
before blood sampling. Based on a meta-analysis 
of ERFC (Emerging Risk Factor Collaboration) in 
2009, the measurement of lipid ratio and the ratio 
of apolipoprotein can be performed without fasting 
prior to the blood sampling.9,10
Previous research has shown some 
atherogenic lipid plasma are independent predictors 
of coronary heart disease, yet research data 
indicates the involvement of specifi c atherogenic 
lipid plasma in ACS is still very limited. These 
studies examine subjects that have not experienced 
or have a history of ACS before, therefore it refl ects 
more or less about chronic effect of the apo B/apo 
A-1 ratio group as a predictor of MACE. Moss et al. 
(1999) examined ACS patients and followed up to 
two months later, and concluded that abnormalities 
in lipid transport, which characterised by low apo 
A-1 and high apo B are independently contribute 
to the incidence of recurrent coronary events.11 
Until now, there is not any study examining the 
relationship between apo B/apo A-1 ratio group 
and occurrence of MACE in ACS patients, 
especially during hospitalisation.
Methods
Subjects
The design of this study was a prospective 
cohort study. The aim was to evaluate the 
relationship between apo B/apo A-1 ratio and 
the occurrence of MACE in ACS patients during 
hospitalisation at  Dr. Sardjito General Hospital 
Yogyakarta from September 2013 until January 
2014. Male and female patients who were 30-85 
years of age and had been admitted to coronary 
care unit with a diagnosis of ACS, and agreed 
to participate in this study were eligible for 
enrolment. Subjects were taken consecutively 
(non-probability sampling) until the minimum 
sample size was achieved. Patients were excluded 
from enrolment if they had an end stage chronic 
kidney disease, chronic heart failure; patients with 
comorbid of sepsis, deep vein thrombosis, acute 
limb ischemia, hepatic cirrhosis, malignancy; 
pregnancy. The subjects were treated at the 
discretion of their attending cardiologists. The 
therapy and medication received at the time of 
baseline enrolment and during hospitalisation 
were recorded.
The demographic characteristics (age, 
gender, body mass index/BMI), risk factors 
for ischemic heart disease (smoking history, 
history of hypertension, diabetes mellitus, 
previous cardiovascular disease and lipid 
disorders), clinical spectrum of ACS, as well 
as the conventional lipid parameters (total 
cholesterol, HDL, LDL, triglyceride), and ratio 
apo B/apo A-1 of the enrolled patients were 
measured within the fi rst 24 hours of admission. 
Other baseline clinical data were recorded, i.e. 
systolic and diastolic blood pressure, routine 
blood tests: hemoglobin, leukocyte numbers 
and numbers of platelets, creatinine, glucose, 
and cardiac enzyme tests (CKMB and troponin 
I). Subsequently, the subjects were followed up 
until discharge from hospital. 
The cl in ical  spectrum of ACS were 
based on symptoms of chest pain of angina, 
electrocardiographic abnormalities and cardiac 
enzyme levels in accordance with the criteria 
ACCF/AHA (2013). The clinical spectrum included 
ST-segment elevation acute myocardial infarction 
(STEMI), non-ST segment elevation acute 
myocardial infarction  (NSTEMI) and unstable 
angina pectoris (UAP). This study was approved 
by the Medical and Health Research Ethics 
Committee at our institution. 
Apolipoprotein measurement
As much as 3 cc of blood samples taken with 
a phlebotomy technique when the patient (fasting 
or non-fasting state) entered the hospital, then 
the blood sample was put in a tube containing 
clot activator. Next, the sample is then centrifuged 
at 2000 rpm for 10 minutes in order to obtain the 
serum to be stored in a -80 °C freezer. Serum 
samples were collected until the sample size is 
met, then will be investigated apo B and apo A-1 
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below the apo B/apo A-1 ratio group simultaneously 
using automated tools imunoturbidimetric method 
(Hitachi 902) and reagent Daiichi (Sekisui Medical, 
Japan). Analyses were performed according to the 
manufacturers’specifi cations, and quality control 
was within the recommended precision for each 
test. 
Study Endpoints
The pre-specifi ed end points were MACE 
during hospitalisation including death of any 
cardiovascular causes, reinfarction, cardiogenic 
shock, acute heart failure, ventricular tachycardia 
or ventricular fibrillation (VT/VF) that require 
cardioversion or defi brillation, prolonged angina, 
acute stroke, as well as the conditions that indicate 
the need for early coronary intervention. Diagnosis 
of these condition was verified by attending 
cardiologists. 
The independent variable in this study is the 
apo B/apo A-1 ratio obtained from the serum of 
patients taken at hospital admission. Dependent 
variable in this study was the occurrence of 
MACE during hospitalisation. While confounding 
variables include the clinical spectrum of acute 
coronary syndromes, age, gender, body mass 
index (BMI), hypertension, diabetes mellitus (DM), 
dyslipidemia, smoking history, family history of 
heart disease, cardiac enzymes (CKMB, troponin 
I), as well as the management of SKA in patients 
during hospitalisation. 
Statistical analysis
Subjects were divided into two groups: 
the group who developed MACE and group 
without MACE (non-MACE). Continuous data 
between groups were compared by unpaired 
t test. Categorical data between groups were 
compared with chi-square test. In the 2x2 tables, 
Fisher exact test was used when Chi-Square test 
requirements are not met. Bivariate analysis was 
conducted to analyze whether the apo B/apo 
A-1 ratio group as a predictor of MACE. For this 
analysis we categorised the value of apo B/apo 
A-1 ratio into 2 categories, high and low apo B/apo 
A-1 ratio group. We determined the cut off point 
using ROC curve analysis. Multivariate analyses 
were performed to see whether the apo B/apo A-1 
ratio group as an independent predictor of MACE. 
Analysis considered signifi cant when the p value 
<0.05. Data analysis was performed with SPSS 
version 22. 
Results
In total, 182 patients met the inclusion 
criteria and thus enrolled in this study. The clinical 
characteristics of the entire study population as 
well as those with and without coronary events 
during follow-up are presented in Table 1.
Clinical characteristic of patients in MACE 
group and control are shown in table 1. There 
are no significant difference in demographic 
characteristics, previous history of hypertension, 
diabetes, dyslipidemia, and coronary artery 
disease, as well as clinical spectrum of ACS 
between the two groups. 
From 182 ACS patients, 51 (28%) patients 
had cardiovascular events (MACE group) and 131 
(72%) patients did not experience MACE (non-
MACE group). In MACE group, there were 11 (6%) 
patients died, 8 (4.4%) incidents of reinfarction, 26 
(14.3%) patients had Killip II-IV, 2 (1.1%) patients 
had prolonged angina, 11 (6%) patients had VT / 
VF requiring cardioversion or defi brillation and/or 
intravenousanti-arrhythmic drugs, 7 (3.8%) patients 
had to be done PCI immediately, and 3 (1.6%) 
patients experienced acute stroke. Patients in MACE 
group showed signifi cant increase of CKMB and 
creatinine value compared to non-MACE group. 
The use of beta-blockers were lower in the MACE 
group, and the invasive (PCI) procedure were higher 
in the MACE group compared to non-MACE group 
(p <0.05) (Table 1).
In this study, we need a cut-off point value 
to classify the apo B/apo A-1 ratio value. In our 
knowledge, there had been no previous studies 
that can be used as a reference value of the 
cut-off point. So we determined the value With 
SPSS, after entering the value of the apo B/apo 
A-1 ratio group into a ROC analysis, we obtained 
a graph as in fi gure 1. Determination of clinical 
cut-off point was defined by the researchers 
as expected and according to study purposes, 
from the point of intersection in ROC (Receiver 
Operating Characteristic) curve analysis. Based 
on research by Walldiuset al. (2001), the value of 
> 0.9 is a high risk of myocardial infarction12, and 
in this present study that value had a sensitivity of 
47-56%, and a specifi city of 51-55%. However, the 
value of 0.865 had  higher sensitivity at 71% and 
specifi city 53%, therefore we determined this value 
to be the optimal cut-off point for apo B/apo A-1 
ratio in this study. Thus, the patients were divided 
into two groups according to apo B/apo A-1 ratio, 
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Table 1. Baseline characteristics of  the subjects based on outcomes (MACE)
Variable Total(n=182)
MACE group 
(n=51)
Non-MACE 
group
(n=131)
P value
Age (years), mean ±SD 60.42 ±10.3 61.0 ±9.9 60.0 ±10.5 0.541
Male/female, n 134/48 36/15 98/33 0.578
BMI (kg/m2), median (span) 23.4 (15.1 – 35.1)
23.6 
(16.8 - 35.1)
23.4 
(15.1-34.2) 0.145
Previous history
Diabetes mellitus, n(%) 58 (31) 21 (41) 37 (29) 0.181
Hypertension, n(%) 124 (68) 38 (74) 85 (64) 0.868
Previous CVD, n(%) 52 (28) 12 (23) 40 (30) 0.347
Smoking, n(%) 105 (57) 22 (43) 83 (63) 0.013
Family history of CVD, n(%) 4 (2) 2 (4) 2 (2) 0.589
Dyslipidemia, n(%) 53 (29) 15 (29) 38 (33) 0.694
ACS clinical spectrum, n(%)
       STEMI
       NSTEMI
       UAP
106 (58)
39 (21)
37 (20)
35 (68.6)
10 (19.6)
6 (11.8)
71 (54.2)
29 (22.1)
31 (23.7)
0.137
Lab. examination
         CKMB, median (span) 46 (3 - 735) 105 (12-735) 41 (3-706) 0.000
         Creatinin (mg/dL),  mean ±SD 1.26 ±0.68 1.4 ±0.95 1.1 ±0.52 0.029
Lipid Parameter, mean±SD 
Total cholesterol, (mg/dL) 184 ±45.8 188.8±42.85 179.88 ±53.26 0.294
Trigliserid, (mg/dL) 123 ±66.8 136.94 ±90.06 119.05 ±54.44 0.120
HDL, (mg/dL) 42 (17 - 189) 40 (17 - 144) 42 (19 - 189) 0.400
LDL, (mg/dL) 117 ±45.6 119.76 ±46.9 115.88 ±45.03 0.501
Apolipoprotein A-1 (g/dL) 102 (28 - 184) 96 (36-145) 104 (28-184) 0.043
Apolipoprotein B (g/dL) 92 ±31.3 89 ±33.4 93 ±30.0 0.467
In-hospital medication and therapy
Heparin, n(%) 163 (89) 43 (26.4) 120 (73.6) 0.149
Beta blocker, n(%) 144 (79) 35 (68) 109 (83) 0.030
Statin, n(%) 160 (87) 46 (93) 114 (98.3) 0.156
Thrombolysis, n(%) 26 (14) 11 (22) 15 (12.9) 0.140
Primary PCI, n(%) 53 (29) 23 (46) 30 (25.9) 0.008
 
Cut-off point : 0.865 
Area Under Curve : 0.59 
Sensitivity : 71% 
Spesificity : 53% 
Figure 1. Receiver-operating characteristics (ROC) curve analysis: determining cut-off point of Apo B/
apo A-1 ratio value based on the incidence of MACE in ACS subjects
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where the value ≥0.865 belong to the high apo B/
apo A-1 ratio group; and value <0.865 as low apo 
B/apo A-1 ratio group.
Table 2 shows that the proportion of subjects 
with MACE in the group with a high apo B/apo A-1 
was higher than the low apo B/apo A-1 ratio group. 
This difference was statistically signifi cant (34% 
vs. 19%; p = 0.028). Patients with the high apo B/
apo A-1 ratio had 1.76 times higher possibility to 
develop MACE compared with patients with the 
low apo B/apo A-1 ratio group.
Table 2.  Association between apo B/apo A-1 ratio and MACE during hospitalization in SKA 
subjects
Variable
End point
RR 95% CI P valueMACE non-MACE
n % n %
High Apo B/ apo A-1 ratio ( ≥0,865)
n = 105 36 34 69 66
1.76 1.040 - 2.97 0.028Low Apo B/ apo A-1 ratio ( <0,865)
n = 77 15 19 62 80
Total 51 28 131 71
Table 3.  Multivariate logistic regression risk analysis of clinical variables 
to occurrence of in-hospital MACE
Variables OR 95% CI P value
STEMI 0.874 0.322 - 2.378 0.793
Beta blocker 0.751 0.231 - 2.439 0.634
Trombolysis 1.488 0.351 - 6.302 0.589
Heparinization 0.496 0.119 - 2.077 0.337
Statin 3.024 0.338 - 27.038 0.322
Creatinin 1.410 0.779 - 2.552 0.256
PCI 0.522 0.217 - 1.258 0.147
Triglyceride 1.005 0.999 - 1.010 0.109
High Apo B/ apo A-1 ratio (≥0,865) 3.171 1.299 - 7.738 0.011*
Smoker 0.275 0.114 - 0.666 0.004*
CKMB 1.008 1.004 - 1.012 0.000*
Remarks: * = statistically signifi cant (p <0.05).
Table 4. Sub analysis of the relationship between the high apo B/apo A-1 ratio with 
each type of MACE
MACE
High Apo 
Ratio
n (%)
Low Apo 
Ratio
n (%)
RR CI 95% p
Death 6 (5.7) 5 (6.5) 0.88 0.279 - 2.779 0.827
Reinfarction 5 (4.8) 3 (3.9) 1.22 0.301 - 4.960 1.000
Kiliip II-IV 18 (17) 8 (10.4) 1.65 0.757 - 3.596 0.198
Prolonged angina 2 (1.9) 0 # # #
VT/VF 6 (5.7) 5 (6.5) 0.88 0.279 - 2.779 1.000
Early PCI 6 (5.7) 1 (1.3) 4.40 0.541 - 35.805 0.241
Acute stroke 3 (2.9) 0 # # #
Description: RR = relative risk; # = Can not be assessed
A multivariate logistic regression model 
was constructed to determine the independent 
contribution that apolipoprotein ratio made to 
occurrence of MACE in the presence of relevant 
clinical variables. Eleven clinical variables entered 
the clinical model at P<0.25 (table 2). Only apo 
B/apo A-1 ratio, smoker, and CKMB entered the 
clinical model at P<0.05, with odds ratio 3.171, 
0.275, and 1.008, respectively (table 3).
We then conducted sub analysis to assess 
the relationship between the high apo B/apo A-1 
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ratio (≥0.865) with the incidence of each type of 
MACE studied (Table 4).
Patients in the high apo B/apo A-1 ratio 
group had a higher proportion of subjects who 
developed deaths (due to any cause), the 
incidence of reinfarction, Killip II-IV, prolonged 
angina, condition requiring early PCI, and the 
incidence of acute stroke than the low Apo B/apo 
A-1 ratio group, but the difference in this proportion 
was not statistically signifi cant.
Discussion
Age, hypertension, smoking and dyslipidemia 
are the most common cardiovascular risk 
factors found in developing countries.13 Baseline 
characteristics of the subjects in this study is 
dominated by subjects with risk factors for old 
age (mean 60 years), male gender, smoking, 
hypertension and dyslipidaemia, but there was 
no statistically signifi cant difference between the 
MACE and non-MACE group. Statistically, the 
basic characteristics of the two groups did not differ 
signifi cantly in terms of demographics, disease 
history and previous CHD risk factors, ACS clinical 
spectrum, as well as standard lipid parameters. 
These indicate that the general characteristics of 
study subjects did not affect the results.
In the ULSAM study (2004) mentioned an 
increase in the apo B/apo A-1 ratio value in line 
with an increased risk of myocardial infarction, 
and the ratio of 0.87-1.23 increases the incidence 
of myocardial infarction up to 30% .14 Thus, the 
cut off point of 0.865 in this study include in 
moderate to high risk category for the occurrence 
of cardiovascular events according to previous 
studies. The analysis of this study showed that in 
ACS patients who have apo B/apo A-1 ratio ≥0.865 
have 1.76 times greater risk of experiencing MACE 
compared with patients with a apo B/apo A-1 ratio 
<0.865 during hospitalisation. Once included in 
the multivariate analysis with logistic regression 
OR of MACE increased to 3.171, so it is evident 
that this apolipoprotein ratio is independent 
predictor factors to the occurrence of MACE during 
hospitalisation in ACS population. This is in line 
with study results by Moss et al. (1999) which 
states that low apo A-1 and high apo B can identify 
patients who experienced recurrent cardiovascular 
events in two months after an ACS.11
Apolipoprotein directly involved in the 
mobilization of lipids and the metabolic conversion 
of the various classes of lipoproteins in circulation. 
Apolipoprotein synthesis influenced by genetic 
control, but can also be infl uenced by diet, hormonal, 
and medical treatment. Apo A-1 is found in the HDL 
and plays an important role in the process of reverse 
cholesterol transport (RCT). In addition, apo A-1 has 
a cofactor activity of the enzyme LCAT, which serves 
cholesterol esterifying hence it is more efficient 
when transported to the liver. Besides, apo A-1 is 
a cholesterol scavenger (cleaners) in circulation. 
Whereasapo B is contained in lipoproteins which is 
known to be atherogenic, i.e LDL, VLDL and sdLDL, 
so the number of Apo B in all atherogenic particles 
likely to be a better risk factor than total cholesterol 
and LDL.
As described previously, apolipoprotein 
might have a role in hemostasis and thrombosis. 
Lipoprotein and apolipoprotein abnormalities, 
especially LDL (apoB-containing) can cause 
endothelial dysfunction by interfering with the balance 
related vasodilation function NO, prostacyclin 
and thromboxane A2. In contrast, HDL, inversely 
correlated with platelet-thrombus formation. Low 
HDL (lower apoA-1 levels) can increase activity of 
PAF and initiated thrombus formation.8,15 Study by 
Moss et al. (1999) mentions that low apoA-1 and 
high apoB independently contribute to recurrent 
coronary events in ACS patients.11 Intravascular 
thrombogenesis process might enhance in patients 
with ACS due to abnormalities in lipoprotein and 
apolipoprotein and will further increase the incidence 
of in-hospital MACE.
Several other variables were also an 
independent predictor to the occurrence of in-
hospital MACE in ACS patients is CKMB levels 
and a history of smoking. Smith et al. (1976) states 
that high levels of CKMB is correlated with an 
extensive area of  myocardial infarction, and hence 
worsen ventricular dysfunction, and then the risk 
of in-hospital MACE.15 In this study showed the 
proportion of smokers in the group MACE lower 
(43%) than in the group of non-MACE (63%). 
And this difference is statistically signifi cant at the 
bivariate and multivariate analysis (p <0.05). But 
in this study, data collection regarding smoking 
history was obtained from the anamneses, and 
thus there is possibility of passive smokers 
subjects included in the group of non-smokers, 
which may further affect the results of this study. 
According to a study by He et al. (1999) mentions 
that passive smokers have an increased risk of 
cardiovascular events.16 Therefore, this study 
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results in respect to smoker as a protective factors 
is still need further investigation.
In MACE group the proportion of beta-
blockers therapy was lower than in non-MACE 
group (68% vs. 83%), and the difference was 
statistically significant proportions. One meta-
analysis by Bangalore et al. (2014) states that 
beta-blocker does not have the effect of reduce 
mortality, but it can reduce the incidence of 
recurrent myocardial infarction and angina (in 
short-term).17 In relation to this study, the lower 
use of beta blockers at MACE group may affect 
the outcome of this study.
In  MACE group,  the propor t ion of 
revascularisation procedure with PCI was signifi cantly 
higher than non-MACE group. The study by Wu et 
al. (2011) described that the primary PCI in STEMI 
population with the results of TIMI fl ow grade (TFG) 
0/1 signifi cantly associated with mortality and the 
incidence of MACE during hospitalisation.18 In this 
study, TFG was not assessed after PCI, so the 
estimation of successful by TFG measurement 
cannot be done objectively. In addition, in our study 
center, PCI procedure has not been done uniformly 
since it is relatively expensive, and constrained by 
fi nancing and health insurance policy.
Our study showed that the lower use of statins 
during hospitalisation can increase the risk of MACE 
of 3 times, but this increase was not statistically 
signifi cant. This is consistent with previous studies 
by Maruyama et al. (2011) which stated that the use 
of statins (pravastatin, atorvastatin or Pitavastatin) 
signifi cantly prevent the occurrence MACE compared 
with no statin therapy in post-PCI patients in Japan.19 
This results indicates that changes in lipid levels from 
baseline (decreased LDL and increased HDL) is 
important in the secondary prevention of MACE.
Study by Snidermanet al. (2007) mentioned 
that in the AMORIS subject population, the risk of 
fatal myocardial infarction increased in line with an 
increasing in the value of apo B/apo A-1 ratio.20 The 
results of our study suggested that subjects with apo 
B/apo A-1 ratio ≥0.865, signifi cantly increasing the 
occurrence of MACE during hospitalisation. In table 
4, in the high apo B/apo A-1 ratio group (≥0.865), 
early PCI procedure increased by 4.4 times, the 
incidence of reinfarction by 1.22 times and Killip≥II 
condition by 1.65 times compared to the low Apo B/
apo A-1 ratio group (<0.865), but this increase was 
statistically not signifi cant (p> 0.05). APSIS (Angina 
Prognosis Study In Stockholm) study stated that 
low apo A-1 and high apo B ratio is an independent 
predictor of revascularisation done in stable angina 
pectoris populations.22 Study Moss et al. (1999) 
states that the value of high apo B and apo A-1 low 
is a statistically signifi cant predictor of the incidence 
of reinfarction in ACS population.11 In our study, this 
results is not signifi cant statistically, probably due to 
lack of power for this subanalysis.
Study Limitations
This study did not analyse the type and 
dose of statins used, where it is known that 
administration of statins in different preparations 
with different dosages, will yield a different therapy 
intensity and response. Furthermore, in this study, 
we did not adjust the MACE outcomes with any 
other valid prognostic score that already exist 
such as GRACE or TIMI risk score. Dyslipidemia 
therapy target based on this parameters can be 
considered and might also help to predict in-
hospital major cardiovascular events, especially 
in ACS patients. Further research is needed on 
the effect of the apo B/apo A-1 ratio on MACE, 
adjusted to valid prognostic scores such as 
GRACE and TIMI risk score.
Conclusions 
High apo B/apo A-1 ratio (≥0.865) is an 
independent predictor of MACE, with an increased 
risk of 3-fold compared to low apo B/apo A-1 ratio 
group (<0.865) in patients with ACS.
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